Targeting Strategy: Bacteriophage Receptor-Binding ProteinDecorated Nanocarriers for Enhanced S. aureus Treatment

Dokuz S., Çoksu İ., Taşdurmazlı S., Erdoğdu B., Acar S., Özbek T.

1st International Symposium on Advances in Phage Therapeutics , Braga, Portekiz, 16 - 17 Haziran 2025, ss.64, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Braga
  • Basıldığı Ülke: Portekiz
  • Sayfa Sayıları: ss.64
  • Yıldız Teknik Üniversitesi Adresli: Evet

Özet

TARGETING STRATEGY: BACTERIOPHAGE RECEPTOR-BINDING PROTEIN-DECORATED NANOCARRIERS FOR ENHANCED S. aureus TREATMENT

Senanur DOKUZ1, Irem COKSU2, Semra TASDURMAZLI1, Berna ERDOGDU1, Serap ACAR2, Tulin OZBEK1*

1Yildiz Technical University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, Istanbul, Turkey

2Yildiz Technical University, Faculty of Chemical and Metallurgical, Department of Bioengineering, Istanbul, Turkey

Keywords: Receptor binding protein, targeted nanoparticle, S. aureus infection

Background and aims: Combining the advantages of nanocarriers with the precision of bacteriophage-based solutions in the fight against bacterial infections is approaches that will strengthen our hand in treatment. In this study, after determining the potential of phage K receptor binding protein (recombinantly produced rGp144) as a targeting agent, rifampicin-loaded PLGA nanoparticle (RIF144-NP) decorated with it was synthesized, characterized and evaluated for its in vitro antimicrobial activity.

Methods: Specific targeting of rGp144 was demonstrated by confocal microscopy and ELISA. Nanoparticles were synthesized by nanoprecipitation method and coated with rGp144. The particle size, zeta potential, drug loading value and drug release profile of nanoparticles were examined. Their antibacterial activity is determined by broth microdilution, time-dependent-growth-curve and agar-well diffusion methods against resistant and sensitive S. aureus strains.

Results: The binding of rGp144 to both S. aureus and methicillin-resistant S. aureus (MRSA) was demonstrated by confocal microscopy, with a capture efficiency of over 87% was determined by ELISA. The drug loading capacity of RIF144-NP with a size of 300 nm and a zeta potential of -11 mV was obtained as 26.64% and the nanosystem continued to release for 4 days. The nanoparticles reduced the MIC twofold in all strains (for MRSA;0.0012µg/mL), moreover in agar-well diffusion; for 0.015µg/mL, RIF144-NP against MRSA had a 9 mm zone, but not at RIF-NP and free antibiotic.

Conclusions: RIF144-NP proved to be much more effective in bacterial elimination in all strains studied compared to free antibiotic and non-targeted nanoparticle. These findings underline the superior antibacterial potential of RIF144-NP in the treatment of S. aureus.